Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSE:4576'
s PB Ratio Range Over the Past 10 Years
Min: 2.56 Med: 4.13 Max: 13.51
Current: 3.25
During the past 13 years, D. Western Therapeutics Institute's highest PB Ratio was 13.51. The lowest was 2.56. And the median was 4.13.
TSE:4576's PB Ratio is ranked worse than 56.64% of 1227
companies
in the Biotechnology industry
Industry Median: 2.82
vs TSE:4576: 3.25
During the past 12 months, D. Western Therapeutics Institute's average Book Value Per Share Growth Rate was 50.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -24.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -24.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -12.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of D. Western Therapeutics Institute was 49.80% per year. The lowest was -36.30% per year. And the median was -3.70% per year.
Back to Basics: PB Ratio
D. Western Therapeutics Institute (TSE:4576) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
D. Western Therapeutics Institute PB Ratio Related Terms
D. Western Therapeutics Institute PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, D. Western Therapeutics Institute's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
D. Western Therapeutics Institute PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's PB Ratio distribution charts can be found below:
* The bar in red indicates where D. Western Therapeutics Institute's PB Ratio falls into.
D. Western Therapeutics Institute PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
D. Western Therapeutics Institute (TSE:4576) has a PB Ratio of 3.25 as of Jul. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on D. Western Therapeutics Institute and its competitors. This is 21% below median its historical median of 4.13. Over the past decade, D. Western Therapeutics Institute's PB Ratio has ranged from 2.56 to 13.51. According to the industry distribution chart, D. Western Therapeutics Institute ranks #695 out of 1227 companies in the Biotechnology industry, placing it in the top 56.6%.
Is D. Western Therapeutics Institute's PB Ratio too high?
D. Western Therapeutics Institute's current PB Ratio of 3.25 is 21% below median its 10-year median of 4.13. Over the past 10 years, this metric has ranged from a low of 2.56 to a high of 13.51. The Biotechnology industry median PB Ratio is 2.82. D. Western Therapeutics Institute's value of 3.25 is 15.2% above this industry median. Based on the distribution chart, D. Western Therapeutics Institute ranks #695 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, D. Western Therapeutics Institute has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, D. Western Therapeutics Institute ranks #695 out of 1227 companies for PB Ratio. This places D. Western Therapeutics Institute in the lower half of its industry. The industry median PB Ratio is 2.82. D. Western Therapeutics Institute's value of 3.25 is 15.2% above this benchmark. Historically, D. Western Therapeutics Institute's own PB Ratio has ranged from 2.56 to 13.51 over the past decade. While the company's 10-year median is 4.13 vs. the industry median of 2.82, D. Western Therapeutics Institute has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. D. Western Therapeutics Institute's current PB Ratio of 3.25 is 15.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on D. Western Therapeutics Institute and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. D. Western Therapeutics Institute's current PB Ratio is 3.25, which is 21% below median its own 10-year median of 4.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (TSE:4576) is currently considered Modestly Overvalued. The stock's GF Value™ is 円68.69, compared to a current price of 円78.00 — trading 13.6% above its estimated fair value. The current PB Ratio is 3.25, which is 21% below median its 10-year median of 4.13 and 15.2% above the Biotechnology industry median of 2.82. D. Western Therapeutics Institute's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For D. Western Therapeutics Institute (TSE:4576), the current PB Ratio is 3.25 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is D. Western Therapeutics Institute (TSE:4576) Overvalued in 2026?
Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued.
The current stock price of 円78.00 is trading 13.6% above its estimated GF Value™ of 円68.69.
GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.
Key valuation signals for TSE:4576:
PB Ratio: 3.25 (21% below median its 10-year median of 4.13)
GF Value™: 円68.69 vs. price of 円78.00 (13.6% above fair value)
Industry Position: 15.2% above the Biotechnology median (#695 of 1227)
No single metric tells the full story. See the TSE:4576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
D. Western Therapeutics Institute Business Description
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
45GF Score
Get the complete analysis for TSE:4576
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4576 has been successfully added to your 
